Journal
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS
Volume 1809, Issue 4-6, Pages 262-268Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbagrm.2011.04.010
Keywords
Iron chelator; Hypoxia inducible factor; Erythropoietin
Categories
Funding
- Defense Advanced Research Projects Agency (DARPA)
- CBER
Ask authors/readers for more resources
Hypoxia inducible factor (HIF-1 alpha) is a master regulator of tissue adaptive responses to hypoxia whose stability is controlled by an iron containing prolyl hydroxylase domain (PHD) protein. A catalytic redox cycle in the PHD's iron center that results in the formation of a ferryl (Fe+4) intermediate has been reported to be responsible for the hydroxylation and subsequent degradation of HIF-1 alpha under normoxia. We show that induction of HIF-1 alpha in rat kidneys can be achieved by iron reduction by the hydroxypyridin-4 one (CP94), an iron chelator administered intraperitoneally in rats. The extent of HIP protein stabilization as well as the expression of HIF target genes, including erythropoietin (EPO), in kidney tissues was comparable to those induced by known inhibitors of the PHD enzyme, such as desferrioxamine (DFO) and cobalt chloride (CoCl2). In human kidney cells and in vitro PHD activity assay, we were able to show that the HIF-1 alpha protein can be stabilized by addition of CP94. This appears to inactivate PHD; and thus prevents the hydroxylation of HIF-1 alpha. In conclusion, we have identified the inhibition of iron-binding pocket of PHD as an underlying mechanism of HIF induction in vivo and in vitro by a bidentate hydroxypyridinone. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available